指南与共识食管胃疾病与幽门螺杆菌消化道肿瘤与早癌消化内镜

走向世界统一方法管理胃黏膜肠上皮化生患者:当前指南综述

The road to a world-unified approach to the management of patients with gastric intestinal metaplasia: a review of current guidelines.
指南 / 共识 · Gut · 2024-09-09

本文系统综述了2010年1月至2023年2月间发布的16部胃黏膜肠上皮化生(GIM)管理指南,旨在综合推荐意见并提供全球视角。各指南在GIM内镜监测目的和高风险表型需定期监测上一致,多数推荐监测间隔3年,均推荐根除幽门螺杆菌,但在组织学分期系统、高质量内镜指标和筛查人群等方面存在异质性。

要点

  • 高风险GIM表型(如累及胃体GIM、OLGIM III/IV期、不完全型GIM)、持续难治性幽门螺杆菌感染或胃癌一级亲属者应定期内镜监测。
  • 低风险表型占多数GIM患者,无需监测。
  • 所有指南推荐根除幽门螺杆菌作为唯一非内镜胃癌预防干预,部分指南额外推荐生活方式调整。

核心结论

  • 尽管人群和实践存在异质性,国际指南普遍认为GIM是癌前病变,需要风险分层内镜监测,并根除幽门螺杆菌。
  • 指南在索引内镜筛查人群、高质量内镜客观指标、组织学分期需求及除根除幽门螺杆菌外的非内镜干预方面有待统一。
  • 需要稳健研究,理想为随机试验,以填补现有证据缺口。

研究设计与样本

  • 系统综述,检索2010年1月至2023年2月发表的指南和共识声明,最终评估16部指南。

主要发现

  • 从426篇文献中识别并评估了16部指南。
  • 各指南一致认为内镜监测目的是发现 prevalent 肿瘤性病变和分期胃癌前状态。
  • 高风险GIM表型、持续难治性幽门螺杆菌感染或胃癌一级亲属家族史者应定期内镜监测,低风险表型无需监测。
  • 并非所有指南在组织学分期系统上一致;若需监测,多数指南推荐3年间隔,但存在变异性。
  • 所有指南推荐根除幽门螺杆菌作为唯一非内镜胃癌预防干预,部分指南提供生活方式调整建议。

关键数值与推荐

  • 高风险GIM表型包括累及胃体GIM、OLGIM III/IV期、不完全型GIM。
  • 若需监测,多数指南推荐3年间隔。
  • 所有指南推荐根除幽门螺杆菌。

临床怎么用

  • 对高风险GIM表型、持续难治性幽门螺杆菌感染或胃癌一级亲属家族史者进行定期内镜监测。
  • 低风险表型占多数GIM患者,无需监测。
  • 根除幽门螺杆菌作为胃癌预防的非内镜干预。
  • 部分指南推荐生活方式调整。

局限性

  • 指南间关于内镜用于胃癌筛查和癌前状态检测的角色存在高度异质性,实施指导有限且缺乏稳健证据。
  • 需要稳健研究,理想为随机试验,以填补证据缺口。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: During the last decade, the management of gastric intestinal metaplasia (GIM) has been addressed by several distinct international evidence-based guidelines. In this review, we aimed to synthesise these guidelines and provide clinicians with a global perspective of the current recommendations for managing patients with GIM, as well as highlight evidence gaps that need to be addressed with future research. DESIGN: We conducted a systematic review of the literature for guidelines and consensus statements published between January 2010 and February 2023 that address the diagnosis and management of GIM. RESULTS: From 426 manuscripts identified, 16 guidelines were assessed. There was consistency across guidelines regarding the purpose of endoscopic surveillance of GIM, which is to identify prevalent neoplastic lesions and stage gastric preneoplastic conditions. The guidelines also agreed that only patients with high-risk GIM phenotypes (eg, corpus-extended GIM, OLGIM stages III/IV, incomplete GIM subtype), persistent refractory Helicobacter pylori infection or first-degree family history of gastric cancer should undergo regular-interval endoscopic surveillance. In contrast, low-risk phenotypes, which comprise most patients with GIM, do not require surveillance. Not all guidelines are aligned on histological staging systems. If surveillance is indicated, most guidelines recommend a 3-year interval, but there is some variability. All guidelines recommend H. pylori eradication as the only non-endoscopic intervention for gastric cancer prevention, while some offer additional recommendations regarding lifestyle modifications. While most guidelines allude to the importance of high-quality endoscopy for endoscopic surveillance, few detail important metrics apart from stating that a systematic gastric biopsy protocol should be followed. Notably, most guidelines comment on the role of endoscopy for gastric cancer screening and detection of gastric precancerous conditions, but with high heterogeneity, limited guidance regarding implementation, and lack of robust evidence. CONCLUSION: Despite heterogeneous populations and practices, international guidelines are generally aligned on the importance of GIM as a precancerous condition and the need for a risk-stratified approach to endoscopic surveillance, as well as H. pylori eradication when present. There is room for harmonisation of guidelines regarding (1) which populations merit index endoscopic screening for gastric cancer and GIM detection/staging; (2) objective metrics for high-quality endoscopy; (3) consensus on the need for histological staging and (4) non-endoscopic interventions for gastric cancer prevention apart from H. pylori eradication alone. Robust studies, ideally in the form of randomised trials, are needed to bridge the ample evidence gaps that exist.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Dinis-Ribeiro M, Shah S, El-Serag H, et al. The road to a world-unified approach to the management of patients with gastric intestinal metaplasia: a review of current guidelines. Gut. 2024. PMID: 39122364. doi:10.1136/gutjnl-2024-333029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。